Statement of Principles concerning Alzheimer disease (Reasonable Hypothesis) (No. 33 of 2019)

The central concept in this instrument is the ‘reasonable hypothesis’. Under section 8, the Repatriation Medical Authority (RMA) declares that there is sound medical‑scientific evidence indicating that Alzheimer disease can be related to relevant service. The instrument then converts that general evidence into a set of specific, necessary factors in section 9. The ‘reasonable hypothesis’ is not a standard of proof on the balance of probabilities or beyond reasonable doubt; it is a threshold that, if met, entitles the claimant to a favourable determination unless the Commission can rebut it.

Alzheimer disease itself is defined in section 7(2) by a four‑part clinical criteria derived from DSM‑5. It requires evidence of major or mild neurocognitive disorder (defined in the Schedule 1 dictionary with reference to significant or modest cognitive decline and impairment on neuropsychological testing), insidious onset and gradual progression without extended plateaus, and either a causative genetic mutation or clear evidence of decline in memory and learning (except for atypical nonamnestic presentations). Importantly, the deficits must not be primarily due to delirium, another mental disorder, or other neurological or systemic conditions. The definition thus excludes many dementias that might mimic Alzheimer’s, such as vascular dementia or Lewy body disease. Death from Alzheimer disease includes death from a terminal event (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) that was contributed to by the Alzheimer disease: section 7(5).

‘Relevant service’ is defined in the Schedule 1 dictionary to mean operational, peacekeeping, hazardous, or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. This limits the instrument’s application to certain categories of service that attract the reasonable hypothesis standard; ordinary peacetime service under the VEA is not included.

The factors in section 9 are the core operational concepts. Each factor must be related to the person’s relevant service under section 10. Some factors apply only to material contribution or aggravation (subsections 9(13) and 9(14)), meaning they can only be used when the disease was suffered or contracted before or during but did not arise out of service.

The instrument also incorporates by reference other Statements of Principles through section 11: if a factor refers to a disease covered by another SoP (e.g., diabetes mellitus), the factors of that other SoP apply as in force from time to time. This creates a layered system where claimants must potentially satisfy multiple SoPs to establish a linking factor.

The primary persons affected are veterans, members of the Peacekeeping Forces, and members of the Forces under the VEA, as well as members under the MRCA (section 8). The instrument applies to claims made under section 120A of the VEA or section 338 of the MRCA (section 5). This covers individuals who have rendered relevant service and who are either currently suffering from Alzheimer disease or have died from it, with a claim for incapacity payments, treatment, or dependants’ benefits.

The instrument also directly affects the Repatriation Commission and the Military Rehabilitation and Compensation Commission as the decision‑making bodies. They are bound to apply these factors when assessing whether a reasonable hypothesis exists. Medical advisers to these commissions, as well as independent specialists engaged to provide opinions, must be familiar with the specific definitions and timeframes.

Claimants’ legal representatives, including veterans’ advocates, solicitors, and barristers, will rely on this instrument to structure their cases. They must obtain evidence that the claimant satisfies at least one factor and that the factor is related to service. The instrument imposes an evidentiary burden on the claimant; the factors are not presumptions but minimum preconditions.

The Repatriation Medical Authority itself is affected in that it must review the scientific evidence periodically and may issue new SoPs. The repeal of the 2010 SoP and commencement of this one on 25 March 2019 means that claims determined after that date are governed by the new criteria.

Indirectly, family members and dependants are affected because their entitlement to dependants’ benefits depends on a successful claim under the VEA or MRCA. The instrument can also affect the timing of claims; for example, the requirement that many factors exist at least ten years before clinical onset may mean that claims for younger veterans will fail unless there is an early‑onset genetic mutation or another factor.

Healthcare providers, especially those diagnosing Alzheimer disease, need to be aware that the instrument’s definition (using DSM‑5 major or mild neurocognitive disorder) may differ from routine clinical diagnosis. The definition excludes certain conditions, and the presence of comorbidities must be ruled out. A doctor’s report that simply states ‘Alzheimer disease’ without confirming the specific criteria may not be sufficient for a claim.

This instrument does not impose any duties on individuals; it is a quasi‑legislative instrument that creates rights and burdens of proof for claimants. The key right it confers is the right to have a claim assessed using the reasonable hypothesis standard, with the benefit of a prescribed list of factors that are accepted as sufficient to raise that hypothesis. If a claimant can demonstrate one of the 14 factors and its connection to service, they are entitled to a decision in their favour unless the decision‑maker can rebut the hypothesis.

The 14 factors themselves can be thought of as the ‘rights‑conferring’ conditions. For example, a veteran who suffered a moderate to severe traumatic brain injury (factor 1) at least ten years before the clinical onset of Alzheimer disease, and who can attribute that injury to service, has a right to have the claim accepted. Similarly, a veteran who smoked at least 20 pack‑years and whose Alzheimer disease onset occurred within five years of cessation (factor 2) may have a claim.

However, the instrument also imposes implicit duties on the claimant: they must provide evidence satisfying the definitions of each factor. For instance, factor 4 (ELF‑EMF) requires a cumulative dose of at least ten microTesla‑years, with exposure from sources like power lines and transformers, excluding background exposure. The claimant must produce evidence of the duration and intensity of exposure during service, which may be difficult to obtain decades later.

Section 10 imposes the requirement that the factor be related to the relevant service rendered by the person. This is not automatic; the claimant must show a causal or temporal connection. Factor 14 (inability to obtain appropriate clinical management) applies only to material contribution or aggravation, not to the initial onset of the disease; it cannot be used for a claim based on contracting Alzheimer disease during service.

The instrument also cross‑references other SoPs under section 11. This creates a duty on the decision‑maker to consider any relevant SoP for the intermediate disease. For example, if a factor is ‘having diabetes mellitus for at least ten years before the clinical onset’, the decision‑maker must apply the SoP concerning diabetes to determine whether the diabetes itself is service‑related. That SoP will have its own factors and definitions.

No rights or duties are created against third parties such as employers or tobacco manufacturers; the instrument only governs the relationship between the veteran and the Commonwealth.

This Statement of Principles does not itself provide for any penalties or enforcement mechanisms. It is not a criminal or regulatory instrument; it is a medical‑scientific directive for adjudicating claims for compensation or benefits. There are no fines, imprisonment, or administrative sanctions set out in its text.

Instead, enforcement occurs at the level of the Repatriation Commission or the Military Rehabilitation and Compensation Commission. If a decision‑maker fails to apply the factors correctly, the claimant can seek review. Under the VEA, internal review by the Repatriation Commission and external review by the Veterans’ Review Board and the Administrative Appeals Tribunal are available. The instrument does not create a private right of action; its enforcement is through administrative law.

However, there is an implicit penalty for claimants who do not meet the factors: their claim will be refused. This is not a penalty in the punitive sense but a denial of entitlement. For some claimants, the inability to satisfy a factor such as the ten‑year latency period for most medical conditions could mean the difference between receiving a disability pension or not.

The instrument itself contains no offence provisions. The only potential for penalties would be if a claimant or representative knowingly provided false or misleading evidence to satisfy a factor, but that would be dealt with under the general criminal law or the VEA provisions on fraud, not under this SoP.

The instrument’s effectiveness depends entirely on the good‑faith application of its definitions and criteria by medical experts and decision‑makers. There is no enforcement body designated. The RMA, which made the instrument, has no ongoing enforcement role once the SoP is published. The litigation history (discussed later) shows that the instrument can be challenged in tribunal or court if a party argues that the factors are not met or that the RMA exceeded its power, but no penalties flow from such challenges.

This instrument operates within the framework of the Veterans’ Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). Specifically, it is made under subsection 196B(2) of the VEA and applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (section 5). Section 120A provides that the standard of proof for certain claims is the ‘reasonable hypothesis’ test, and subsection 120A(3) requires the RMA to determine Statements of Principles. This instrument is thus subordinate legislation under those Acts.

The instrument provides that a reference in another SoP to an injury or disease covered by a SoP means the factors of that other SoP apply as in force from time to time (section 11). This creates an interlocking system. For example, a claimant relying on factor 7 (having diabetes mellitus) will need to have that diabetes accepted as service‑related under the SoP concerning diabetes. That SoP will have its own factors and definitions.

The instrument is expressly stated to apply only to claims under the VEA or MRCA, not to other Commonwealth schemes such as the Safety, Rehabilitation and Compensation Act 1988 (DRCA) or the Social Security Act 1991. However, the definitions in schedule 1 use concepts that may overlap with other areas of law. For example, ‘being obese’ is defined by BMI of 30 or greater, which is the same threshold used in many medical guidelines and some insurance contracts.

The instrument is not a complete code; it does not displace the standard of proof or the rules of evidence that apply in tribunal proceedings. It only defines one element of the reasonable hypothesis test. The decision‑maker must still be satisfied that the hypothesis is reasonable and that the factor is related to service.

The instrument also interacts with state and territory laws in the sense that medical practitioners diagnosing Alzheimer disease must comply with the DSM‑5 criteria specified. The instrument does not override state‑based medical certification, but it sets a higher threshold for the purposes of a veterans’ claim. A clinical diagnosis of ‘probable Alzheimer disease’ may not satisfy the definition in section 7(2) if it does not explicitly rule out other conditions.

The repealed SoP No. 22 of 2010 is no longer operative for new claims after 25 March 2019, but it may still apply to claims made before that date or to appeals where the law in force at the time of original decision is applied.

The instrument is the current SoP concerning Alzheimer disease, having been made on 1 March 2019 and commencing on 25 March 2019. It repeals the previous Statement of Principles concerning Alzheimer‑type dementia No. 22 of 2010 (Federal Register of Legislation No. F2017C00820), which was made under subsections 196B(2) and (8) of the VEA (section 4). The source text does not provide any further amendment history for this instrument itself; it is presented as a standalone final instrument. The earlier 2010 SoP had been amended at least once (compilation F2017C00820 indicates a change in 2017), but those amendments are not detailed here.

The instrument replaces the term ‘Alzheimer‑type dementia’ with ‘Alzheimer disease’ in its title and definitions, which reflects changes in medical nomenclature. The definition now explicitly uses DSM‑5 criteria, whereas the 2010 SoP likely referred to earlier diagnostic standards.

The instrument does not have any subsequent amending instruments within its text. As a legislative instrument registered on the Federal Register of Legislation, it can be amended by a later RMA determination. The user should check the register for any amendments after 2019. The instrument’s commencement date of 25 March 2019 is the date from which it applies. For claims lodged before that date but still undetermined, the old SoP may continue to apply depending on transitional provisions in the VEA or MRCA, which are not addressed in this instrument.

The instrument was made under subsection 196B(2) (reasonable hypothesis SoP), which is distinct from subsection 196B(8) that covers ‘balance of probabilities’ SoPs for malignant cancers or other certain diseases. This indicates that the RMA considers the evidence supports a reasonable hypothesis standard, not a higher standard.

The source text does not contain any reference to litigation. However, as a matter of general context, Statements of Principles made by the RMA have been the subject of judicial review in the Federal Court and the Administrative Appeals Tribunal (AAT). Claimants often challenge decisions that a factor is not met or that the SoP itself is invalid. For example, in earlier litigation, veterans have argued that the RMA failed to consider relevant evidence or that the SoP was medically unsound. The AAT has also considered the meaning of terms such as ‘sound medical‑scientific evidence’ and ‘reasonable hypothesis’ in relation to these SoPs.

No specific cases are cited in the instrument. Users should be aware that the interpretation of factors such as ‘moderate to severe traumatic brain injury’ or ‘inability to undertake any physical activity greater than three METs for at least five years’ may be tested in review. The ten‑year latency requirement for many factors is a common point of contention, especially if the veteran’s exposure during service occurred close to the onset of symptoms.

The instrument’s definition of Alzheimer disease may be litigated where a veteran has a mixed dementia (e.g., Alzheimer disease with vascular components). The definition in section 7(2)(D) excludes cerebrovascular disease as a primary cause, but if the dementia is due to both, the clinical diagnosis may still fall within the definition if the Alzheimer component is the dominant cause.

The repeal of the 2010 SoP means that any previous litigation interpreting that SoP is not directly binding on this new one, though it may be persuasive. The RMA’s own statements in the Basis for determining the factors (section 8) are not reviewable on merits, but the instrument itself can be challenged on procedural grounds, such as a failure to comply with the legislative requirements for consultation or publication.

Several provisions in this instrument can catch claimants and their representatives off guard.

First, the definition of Alzheimer disease in section 7(2) is more restrictive than a typical clinical diagnosis. It requires evidence meeting DSM‑5 criteria for major or mild neurocognitive disorder, plus insidious onset and gradual progression, plus a genetic mutation or a decline in memory and learning. Critically, section 7(2)(D) excludes Alzheimer disease if the cognitive deficits are primarily due to cerebrovascular disease or another neurodegenerative disease. A veteran with mixed vascular dementia and Alzheimer’s may not satisfy the definition unless the Alzheimer component is considered primary. The note refers to atypical presentations, but these are defined narrowly as nonamnestic variants.

Second, the temporal requirements in the factors are strict. Most factors must exist at least ten years before the clinical onset of Alzheimer disease (factors 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). Clinical onset means the time when symptoms first become apparent, not the date of formal diagnosis. Claimants may have difficulty proving exposure or condition exactly ten years prior. For example, factor 5 (obesity) requires being obese for at least ten years before clinical onset. If a veteran became obese during service but lost weight later, they must show that the period of obesity ended at least ten years before onset, which may be impossible if onset occurred soon after service.

Third, factor 2 (smoking) includes a cessation window: if the person ceased smoking, the clinical onset must occur within five years of cessation. This means that veterans who quit smoking more than five years before developing Alzheimer disease cannot use this factor. The calculation of pack‑years is defined with precision: 20 pack‑years means 7,300 cigarettes or 7.3 kg of tobacco. Pipe and cigar tobacco are included by weight.

Fourth, factor 4 (ELF‑EMF) requires a cumulative dose of at least ten microTesla‑years. The definition of cumulative dose excludes background exposure. This is extremely difficult to prove for service that occurred decades ago unless the veteran has detailed records of proximity to power lines or generators. The note gives examples but service personnel rarely have dosimetry records.

Fifth, factor 12 (inability to undertake physical activity greater than three METs for at least five years) is vague. Three METs is roughly equivalent to walking at 2‑3 mph. ‘Inability’ means the person could not achieve that level of exertion. This may capture veterans with severe mobility impairments but not those who simply chose not to exercise.

Sixth, factor 13 (anticholinergic drug use) applies only to clinical worsening, not to initial onset. The specified list includes common antidepressants, antiparkinson agents, and bladder antimuscarinics. Many older veterans may have been prescribed these drugs unrelated to service, so the factor only helps if the worsening occurred after service.

Seventh, factor 14 (inability to obtain appropriate clinical management) also applies only to material contribution or aggravation of an existing condition. It cannot be used for a fresh claim of Alzheimer disease.

Eighth, section 10(2) expressly provides that factors 13 and 14 apply only where the Alzheimer disease was suffered or contracted before or during (but did not arise out of) relevant service. This means they cannot be used if the disease arose out of service; they are for aggravation cases only.

Ninth, the cross‑reference mechanism in section 11 means a veteran claiming a factor such as diabetes must also satisfy the SoP for diabetes. That SoP may have its own restrictive definitions. Claimants cannot simply rely on a doctor saying they have diabetes; they must show that the diabetes is service‑related under the relevant SoP.

Compliance with this instrument is not a matter of active duty for individuals; rather, it is a matter of ensuring that claims are properly evaluated. For legal practitioners and advocates, compliance means gathering evidence that addresses each element of a chosen factor and the definition of Alzheimer disease.

For a claimant, the first step is to obtain a diagnosis of Alzheimer disease that meets the DSM‑5 criteria of section 7(2). A medical report should explicitly state that the patient has major or mild neurocognitive disorder with insidious onset and gradual progression, and should rule out the exclusions in subsection 7(2)(D). If the claimant has a genetic mutation, that should be documented. If there is no genetic testing, the report should confirm decline in memory and learning (or an atypical presentation).

The second step is to identify which of the 14 factors in section 9 potentially applies. The factor must be related to the claimant’s relevant service (section 10). For example, if the claimant served in a combat zone and suffered a moderate to severe traumatic brain injury, the advocate should obtain medical records documenting the injury (e.g., GCS score, loss of consciousness, post‑traumatic amnesia). The factor requires at least ten years before clinical onset, so the chronology must be established.

For factor 2 (smoking), evidence of quantity and duration of smoking is required, and if cessation occurred, the five‑year window must be met. Service records or self‑reports should be corroborated by medical notes. Pack‑year calculation uses the defined formula.

For factor 4 (ELF‑EMF), an expert engineering or occupational hygiene report may be needed to estimate the cumulative dose based on job duties and equipment. The claimant must show exposure to sources such as power lines or transformers during service, and the dose calculation must exclude background. This is one of the most onerous factors to prove.

For metabolic factors (obesity, dyslipidaemia, diabetes, hypertension, hyperhomocysteinaemia), medical records must show the condition existed for at least ten years before clinical onset. The definitions in the dictionary provide thresholds: BMI 30+ for obesity; abnormal lipid profile after a 12‑hour fast; diabetes mellitus diagnosed by standard criteria; hypertension; and hyperhomocysteinaemia. Claimants should have contemporaneous blood test results.

For psychiatric factors (major depressive disorder, PTSD), a diagnosis by a psychiatrist or psychologist consistent with DSM‑5 is needed, and the condition must have been present for at least ten years before Alzheimer onset. Many veterans may have had these conditions but not sought treatment; proving their existence and duration may require expert evidence based on history.

For factor 12 (inability to undertake physical activity >3 METs), evidence of a medical condition or injury that rendered the claimant unable to walk briskly is needed, for a continuous period of at least five years.

If the claim is for worsening of an existing Alzheimer disease, factors 13 and 14 may be used. The claimant must show that at the time of worsening they were taking an anticholinergic drug from the specified list (factor 13) or were unable to obtain appropriate clinical management (factor 14). The list is exhaustive; if the drug is not listed, it does not apply.

Finally, the claim should be accompanied by evidence that the chosen factor is related to service. This may require linking the traumatic brain injury to a specific incident, or showing that the veteran’s smoking habit started or increased due to service conditions. The VEA and MRCA have their own provisions about what constitutes service‑related.

The Repatriation Commission or MRCC will then assess whether the evidence supports a reasonable hypothesis. If the claimant cannot produce adequate evidence, the claim will be refused unless the decision‑maker can find alternative factors. Compliance is thus evidentiary: all definitions and timeframes must be strictly addressed.